Quinolone derivative, flumequine, as short-term treatment for gonorrhoea.
The antigonococcal activity of the quinolone derivative flumequine was evaluated. Of 246 strains examined, 240 (97.5%) strains showed minimum inhibitory concentrations (MICs) of flumequine of less than or equal to 0.4 microgram/ml, including three beta-lactamase-producing strains. The six remaining strains showed MICs from 3.2 to 9.6 micrograms/ml. By disc diffusion tests using 3-micrograms discs of flumequine the zones of growth inhibition correlated well with the MICs of flumequine. The effect of treatment with flumequine was compared in 239 patients with uncomplicated gonorrhoea. A single dose regimen of 1200 mg flumequine orally, a two-dose regimen of 1200 and 800 mg, and a three-dose regimen of 1200, 800, and 800 mg (six hours apart) were given. With a single dose of flumequine the failure rate was 26%. The two-dose and three-dose regimens were equally effective with an overall cure rate of 95.4%. In patients harbouring beta-lactamase-producing gonococci the infection was cured. The failures (10 men) included all of the six patients infected with flumequine-resistant gonococci. Side effects were noted by 14.6% of the patients and were mostly described as dizziness.
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009344:Neisseria gonorrhoeae / Q000201:enzymology; D011807:Quinolizines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D011807:Quinolizines; D001618:beta-Lactamases; C012976:flumequine